News & Press Releases
News & Press Releases
News & Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Put Option exercised by PsyLabs initiates a $5 million share for share exchange, deepening strategic alignment and reinforcing long term access to pharmaceutical grade psychedelic supply as clinical programs advance.
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence BioMed Annual and Special Meeting results confirm shareholder approval of directors, auditors and potential share consolidation authority of up to 250 to 1.
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world's most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds.
Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS").
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence Biomed today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.
News and Press Releases
Here you’ll find official announcements, company updates, and press releases from Psyence Biomed. This page provides verified, up-to-date information on our progress, partnerships, clinical milestones, and corporate developments.
We believe in keeping our stakeholders informed and engaged with clear and timely communication. Whether it’s news about our scientific breakthroughs, regulatory updates, or leadership commentary, this is your trusted source for all formal communications from Psyence Biomed.
All press releases are archived for reference and can be accessed at any time. For journalists or media professionals, please reach out to our team through the Contact page for further information or interviews.
